29/07/2026 22:58 - Salud
The battle against Alzheimer’s disease just took an exciting turn. Researchers at Cardiff University in the United Kingdom have uncovered a critical link between common viral infections and the development of this devastating condition. The best part? This discovery points to preventive strategies we might already have at our disposal—like antiviral drugs—to protect our brains for years to come.
The study, published on July 29, 2026 in the prestigious journal Oxford Academic, showed that infection with a herpesvirus not only worsens memory problems but also accelerates the buildup of abnormal proteins and neuron loss in the hippocampus—the brain’s memory and learning center.
To understand this breakthrough, we need to meet the culprit: herpesviruses. This large family includes everything from the virus that causes cold sores to cytomegalovirus (CMV) and the agents behind mononucleosis and childhood infections. Their superpower? After an initial infection, they can stay dormant in our bodies and reactivate later in life.
Dr. Mathew Clement from Cardiff’s School of Medicine explained that scientists have long suspected these chronic viruses increase Alzheimer’s risk, but the exact mechanisms remained a mystery. Until now!
The team used 3xTg-AD transgenic mice, a well-established model that carries genetic mutations making them prone to develop Alzheimer’s-like features. They infected these mice with murine cytomegalovirus (MCMV), a type of herpesvirus.
The results were striking: the infection accelerated cognitive decline, tauopathy (abnormal tau protein buildup), and synaptic loss in the hippocampus. But the damage wasn’t caused by the virus alone—it was the prolonged immune response that, while trying to control the infection, ended up harming vulnerable brain tissue.
The study found that CD8+ T cells (our immune system’s soldiers) flooded into the brain to fight the virus. However, this sustained inflammation turned out to be an active driver of neurodegeneration, not just a bystander.
The most encouraging finding came when the researchers intervened. Mice treated with the antiviral valganciclovir or those with reduced T cell levels showed a remarkable decrease in brain infiltrates and, most importantly, improved cognitive performance!
Professor Ian Humphreys, co-director of the Systems Immunity Research Institute, emphasized that understanding how these cells act in the brain could provide revolutionary insights for treating Alzheimer’s.
This new perspective frames Alzheimer’s as the result of interactions between our genetics, environment, and immune system. Currently, Alzheimer’s affects about 50 million people worldwide, with projections reaching 152 million by 2050. But there is hope!
As Dr. Clement concluded, dementia risk isn’t solely determined by genetics. By preventing infections through vaccines, antiviral treatments, and strengthening our immune system, we not only avoid short-term illnesses but also actively reduce the risk of dementia in the future. Taking care of our defenses today means protecting our memories tomorrow.
Alfredo S. Quiroga
